AU2020276296A1 - NK cell-directed chimeric proteins - Google Patents

Info

Publication number

AU2020276296A1

AU2020276296A1 AU2020276296A AU2020276296A AU2020276296A1 AU 2020276296 A1 AU2020276296 A1 AU 2020276296A1 AU 2020276296 A AU2020276296 A AU 2020276296A AU 2020276296 A AU2020276296 A AU 2020276296A AU 2020276296 A1 AU2020276296 A1 AU 2020276296A1

Authority

AU

Australia

Prior art keywords

chimeric protein

domain

nkg2a

cells

protein

Prior art date

2019-05-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 108020001507 fusion proteins Proteins 0.000 title claims abstract description 734
• 102000037865 fusion proteins Human genes 0.000 title claims abstract description 734
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 175
• 238000011282 treatment Methods 0.000 claims abstract description 70
• 238000000034 method Methods 0.000 claims abstract description 68
• 201000011510 cancer Diseases 0.000 claims abstract description 67
• 108091005906 Type I transmembrane proteins Proteins 0.000 claims abstract description 44
• 108050001049 Extracellular proteins Proteins 0.000 claims abstract description 37
• 108091005956 Type II transmembrane proteins Proteins 0.000 claims abstract description 35
• 208000036142 Viral infection Diseases 0.000 claims abstract description 32
• 230000009385 viral infection Effects 0.000 claims abstract description 32
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
• 201000010099 disease Diseases 0.000 claims abstract description 10
• 210000004027 cell Anatomy 0.000 claims description 352
• 230000027455 binding Effects 0.000 claims description 266
• 239000003446 ligand Substances 0.000 claims description 178
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 154
• 102000005962 receptors Human genes 0.000 claims description 111
• 108020003175 receptors Proteins 0.000 claims description 111
• 239000003795 chemical substances by application Substances 0.000 claims description 102
• 241000282414 Homo sapiens Species 0.000 claims description 81
• 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 78
• 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 63
• 239000008194 pharmaceutical composition Substances 0.000 claims description 45
• 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 claims description 42
• 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 42
• 102100036008 CD48 antigen Human genes 0.000 claims description 39
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 37
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 35
• 210000000822 natural killer cell Anatomy 0.000 claims description 35
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 34
• 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 33
• 101150036449 SIRPA gene Proteins 0.000 claims description 32
• 230000004913 activation Effects 0.000 claims description 31
• 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims description 29
• 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 claims description 29
• 102100029197 SLAM family member 6 Human genes 0.000 claims description 26
• 150000007523 nucleic acids Chemical class 0.000 claims description 26
• 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 claims description 25
• 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 claims description 25
• 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims description 25
• 230000002401 inhibitory effect Effects 0.000 claims description 24
• 101150069255 KLRC1 gene Proteins 0.000 claims description 23
• 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims description 23
• 108020004707 nucleic acids Proteins 0.000 claims description 23
• 102000039446 nucleic acids Human genes 0.000 claims description 23
• -1 NKG2B Proteins 0.000 claims description 22
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 21
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 21
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 21
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 20
• 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 claims description 20
• 230000003993 interaction Effects 0.000 claims description 20
• 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 claims description 19
• 239000013604 expression vector Substances 0.000 claims description 19
• 229960003301 nivolumab Drugs 0.000 claims description 19
• 239000003814 drug Substances 0.000 claims description 18
• 210000004881 tumor cell Anatomy 0.000 claims description 18
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 17
• 230000001506 immunosuppresive effect Effects 0.000 claims description 17
• 238000004519 manufacturing process Methods 0.000 claims description 16
• 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 claims description 15
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
• 230000004936 stimulating effect Effects 0.000 claims description 15
• 229920001184 polypeptide Polymers 0.000 claims description 14
• 208000015181 infectious disease Diseases 0.000 claims description 13
• 229960002621 pembrolizumab Drugs 0.000 claims description 12
• 230000000259 anti-tumor effect Effects 0.000 claims description 11
• 241000700605 Viruses Species 0.000 claims description 10
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 10
• 230000002459 sustained effect Effects 0.000 claims description 10
• 108010074708 B7-H1 Antigen Proteins 0.000 claims description 9
• 206010009944 Colon cancer Diseases 0.000 claims description 9
• 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 9
• 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 9
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 9
• 102000004127 Cytokines Human genes 0.000 claims description 8
• 108090000695 Cytokines Proteins 0.000 claims description 8
• 230000005540 biological transmission Effects 0.000 claims description 8
• 208000032839 leukemia Diseases 0.000 claims description 8
• 230000035755 proliferation Effects 0.000 claims description 8
• 230000009467 reduction Effects 0.000 claims description 7
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 6
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 6
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 6
• 230000002159 abnormal effect Effects 0.000 claims description 6
• 230000002519 immonomodulatory effect Effects 0.000 claims description 6
• 229960003347 obinutuzumab Drugs 0.000 claims description 6
• 210000000225 synapse Anatomy 0.000 claims description 6
• 241000725303 Human immunodeficiency virus Species 0.000 claims description 5
• 206010025323 Lymphomas Diseases 0.000 claims description 5
• 229960005395 cetuximab Drugs 0.000 claims description 5
• 210000001072 colon Anatomy 0.000 claims description 5
• 230000005764 inhibitory process Effects 0.000 claims description 5
• 201000001441 melanoma Diseases 0.000 claims description 5
• 230000008054 signal transmission Effects 0.000 claims description 5
• 206010006187 Breast cancer Diseases 0.000 claims description 4
• 201000009030 Carcinoma Diseases 0.000 claims description 4
• 206010014733 Endometrial cancer Diseases 0.000 claims description 4
• 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
• 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
• 206010038389 Renal cancer Diseases 0.000 claims description 4
• 102100031778 SH2 domain-containing protein 1B Human genes 0.000 claims description 4
• 101100528457 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RMP1 gene Proteins 0.000 claims description 4
• 241000700584 Simplexvirus Species 0.000 claims description 4
• 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
• 230000004663 cell proliferation Effects 0.000 claims description 4
• 230000001684 chronic effect Effects 0.000 claims description 4
• 230000003325 follicular Effects 0.000 claims description 4
• 206010017758 gastric cancer Diseases 0.000 claims description 4
• 210000003734 kidney Anatomy 0.000 claims description 4
• 201000010982 kidney cancer Diseases 0.000 claims description 4
• 230000002147 killing effect Effects 0.000 claims description 4
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
• 229950010773 pidilizumab Drugs 0.000 claims description 4
• 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims description 4
• 206010038038 rectal cancer Diseases 0.000 claims description 4
• 201000001275 rectum cancer Diseases 0.000 claims description 4
• 210000002345 respiratory system Anatomy 0.000 claims description 4
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
• 201000011549 stomach cancer Diseases 0.000 claims description 4
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
• 208000026310 Breast neoplasm Diseases 0.000 claims description 3
• 241000557626 Corvus corax Species 0.000 claims description 3
• 241000710781 Flaviviridae Species 0.000 claims description 3
• 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 3
• 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 3
• 101000707218 Homo sapiens SH2 domain-containing protein 1B Proteins 0.000 claims description 3
• 101150074862 KLRC3 gene Proteins 0.000 claims description 3
• 101150018199 KLRC4 gene Proteins 0.000 claims description 3
• 241000713666 Lentivirus Species 0.000 claims description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
• 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 3
• 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 3
• 102100022701 NKG2-E type II integral membrane protein Human genes 0.000 claims description 3
• 102100022700 NKG2-F type II integral membrane protein Human genes 0.000 claims description 3
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
• 208000029742 colonic neoplasm Diseases 0.000 claims description 3
• 229960002204 daratumumab Drugs 0.000 claims description 3
• 229940057296 gatipotuzumab Drugs 0.000 claims description 3
• 229950005015 inebilizumab Drugs 0.000 claims description 3
• 229940050282 inebilizumab-cdon Drugs 0.000 claims description 3
• 229960005386 ipilimumab Drugs 0.000 claims description 3
• 201000007270 liver cancer Diseases 0.000 claims description 3
• 208000014018 liver neoplasm Diseases 0.000 claims description 3
• 210000004072 lung Anatomy 0.000 claims description 3
• 229950003135 margetuximab Drugs 0.000 claims description 3
• 229950007699 mogamulizumab Drugs 0.000 claims description 3
• 229950009090 ocaratuzumab Drugs 0.000 claims description 3
• 229960004641 rituximab Drugs 0.000 claims description 3
• 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
• 229940121503 tafasitamab Drugs 0.000 claims description 3
• 229940060960 tomuzotuximab Drugs 0.000 claims description 3
• 229960000575 trastuzumab Drugs 0.000 claims description 3
• 229950004593 ublituximab Drugs 0.000 claims description 3
• 229940055760 yervoy Drugs 0.000 claims description 3
• 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
• 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
• 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
• 206010005003 Bladder cancer Diseases 0.000 claims description 2
• 206010005949 Bone cancer Diseases 0.000 claims description 2
• 208000018084 Bone neoplasm Diseases 0.000 claims description 2
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
• 208000009458 Carcinoma in Situ Diseases 0.000 claims description 2
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
• 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
• 241000709687 Coxsackievirus Species 0.000 claims description 2
• 241000725619 Dengue virus Species 0.000 claims description 2
• 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 2
• 241000709661 Enterovirus Species 0.000 claims description 2
• 241000991587 Enterovirus C Species 0.000 claims description 2
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
• 241000711549 Hepacivirus C Species 0.000 claims description 2
• 208000017604 Hodgkin disease Diseases 0.000 claims description 2
• 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
• 241000342334 Human metapneumovirus Species 0.000 claims description 2
• 241000710842 Japanese encephalitis virus Species 0.000 claims description 2
• 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
• 206010025312 Lymphoma AIDS related Diseases 0.000 claims description 2
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
• 241000712079 Measles morbillivirus Species 0.000 claims description 2
• 208000006395 Meigs Syndrome Diseases 0.000 claims description 2
• 206010027139 Meigs' syndrome Diseases 0.000 claims description 2
• 241000711386 Mumps virus Species 0.000 claims description 2
• 206010029260 Neuroblastoma Diseases 0.000 claims description 2
• 206010030113 Oedema Diseases 0.000 claims description 2
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
• 241000150452 Orthohantavirus Species 0.000 claims description 2
• 241000712464 Orthomyxoviridae Species 0.000 claims description 2
• 206010033128 Ovarian cancer Diseases 0.000 claims description 2
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
• 208000009608 Papillomavirus Infections Diseases 0.000 claims description 2
• 241000711504 Paramyxoviridae Species 0.000 claims description 2
• 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 2
• 241000150350 Peribunyaviridae Species 0.000 claims description 2
• 206010048734 Phakomatosis Diseases 0.000 claims description 2
• 241000709664 Picornaviridae Species 0.000 claims description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
• 206010060862 Prostate cancer Diseases 0.000 claims description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
• 241000702247 Reoviridae Species 0.000 claims description 2
• 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
• 201000000582 Retinoblastoma Diseases 0.000 claims description 2
• 241000712907 Retroviridae Species 0.000 claims description 2
• 241000702670 Rotavirus Species 0.000 claims description 2
• 241001533467 Rubulavirus Species 0.000 claims description 2
• 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
• 206010039491 Sarcoma Diseases 0.000 claims description 2
• 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
• 241000710888 St. Louis encephalitis virus Species 0.000 claims description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
• 206010057644 Testis cancer Diseases 0.000 claims description 2
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
• 206010047741 Vulval cancer Diseases 0.000 claims description 2
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
• 241000710886 West Nile virus Species 0.000 claims description 2
• 241000710772 Yellow fever virus Species 0.000 claims description 2
• 230000001154 acute effect Effects 0.000 claims description 2
• 201000009036 biliary tract cancer Diseases 0.000 claims description 2
• 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
• 201000000220 brain stem cancer Diseases 0.000 claims description 2
• 229940121420 cemiplimab Drugs 0.000 claims description 2
• 201000007455 central nervous system cancer Diseases 0.000 claims description 2
• 201000010881 cervical cancer Diseases 0.000 claims description 2
• 201000010918 connective tissue cancer Diseases 0.000 claims description 2
• 201000004101 esophageal cancer Diseases 0.000 claims description 2
• 208000024519 eye neoplasm Diseases 0.000 claims description 2
• 208000005017 glioblastoma Diseases 0.000 claims description 2
• 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
• 201000010536 head and neck cancer Diseases 0.000 claims description 2
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
• 230000002440 hepatic effect Effects 0.000 claims description 2
• 208000006454 hepatitis Diseases 0.000 claims description 2
• 231100000283 hepatitis Toxicity 0.000 claims description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
• 208000020082 intraepithelial neoplasia Diseases 0.000 claims description 2
• 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
• 201000004962 larynx cancer Diseases 0.000 claims description 2
• 210000000088 lip Anatomy 0.000 claims description 2
• 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
• 201000005202 lung cancer Diseases 0.000 claims description 2
• 208000020816 lung neoplasm Diseases 0.000 claims description 2
• 230000000527 lymphocytic effect Effects 0.000 claims description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
• 230000000873 masking effect Effects 0.000 claims description 2
• 210000000214 mouth Anatomy 0.000 claims description 2
• 208000025113 myeloid leukemia Diseases 0.000 claims description 2
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
• 201000008106 ocular cancer Diseases 0.000 claims description 2
• 201000005443 oral cavity cancer Diseases 0.000 claims description 2
• 201000002528 pancreatic cancer Diseases 0.000 claims description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
• 201000002628 peritoneum cancer Diseases 0.000 claims description 2
• 210000003800 pharynx Anatomy 0.000 claims description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
• 201000003804 salivary gland carcinoma Diseases 0.000 claims description 2
• 201000000849 skin cancer Diseases 0.000 claims description 2
• 208000017572 squamous cell neoplasm Diseases 0.000 claims description 2
• 201000003120 testicular cancer Diseases 0.000 claims description 2
• 201000002510 thyroid cancer Diseases 0.000 claims description 2
• 210000002105 tongue Anatomy 0.000 claims description 2
• 229950007217 tremelimumab Drugs 0.000 claims description 2
• 241000712461 unidentified influenza virus Species 0.000 claims description 2
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
• 230000002485 urinary effect Effects 0.000 claims description 2
• 206010046766 uterine cancer Diseases 0.000 claims description 2
• 230000002792 vascular Effects 0.000 claims description 2
• 210000001835 viscera Anatomy 0.000 claims description 2
• 201000005102 vulva cancer Diseases 0.000 claims description 2
• 229940051021 yellow-fever virus Drugs 0.000 claims description 2
• 108010021064 CTLA-4 Antigen Proteins 0.000 claims 4
• 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
• 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims 1
• 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims 1
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
• 239000000203 mixture Substances 0.000 abstract description 24
• 125000005647 linker group Chemical group 0.000 description 202
• 108090000623 proteins and genes Proteins 0.000 description 82
• 235000018102 proteins Nutrition 0.000 description 74
• 102000004169 proteins and genes Human genes 0.000 description 74
• 231100000673 dose–response relationship Toxicity 0.000 description 64
• 241000699670 Mus sp. Species 0.000 description 63
• 238000005304 joining Methods 0.000 description 60
• 239000003638 chemical reducing agent Substances 0.000 description 59
• 241000699666 Mus <mouse, genus> Species 0.000 description 58
• 230000001965 increasing effect Effects 0.000 description 47
• 230000022811 deglycosylation Effects 0.000 description 45
• 235000001014 amino acid Nutrition 0.000 description 44
• 230000014509 gene expression Effects 0.000 description 44
• 210000001744 T-lymphocyte Anatomy 0.000 description 40
• 238000006467 substitution reaction Methods 0.000 description 39
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 36
• 229940045513 CTLA4 antagonist Drugs 0.000 description 35
• 230000035772 mutation Effects 0.000 description 35
• 210000003289 regulatory T cell Anatomy 0.000 description 35
• 238000001262 western blot Methods 0.000 description 34
• 239000013642 negative control Substances 0.000 description 33
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 32
• 238000000684 flow cytometry Methods 0.000 description 30
• 238000012286 ELISA Assay Methods 0.000 description 29
• 229940024606 amino acid Drugs 0.000 description 29
• 150000001413 amino acids Chemical class 0.000 description 27
• 238000012512 characterization method Methods 0.000 description 26
• 239000012636 effector Substances 0.000 description 25
• 230000002829 reductive effect Effects 0.000 description 25
• 241001529936 Murinae Species 0.000 description 23
• 125000000539 amino acid group Chemical group 0.000 description 23
• 230000006870 function Effects 0.000 description 22
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 22
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 20
• 210000003162 effector t lymphocyte Anatomy 0.000 description 20
• 230000000694 effects Effects 0.000 description 20
• 230000011664 signaling Effects 0.000 description 19
• 102000035160 transmembrane proteins Human genes 0.000 description 16
• 108091005703 transmembrane proteins Proteins 0.000 description 16
• 239000000427 antigen Substances 0.000 description 15
• 108091007433 antigens Proteins 0.000 description 15
• 102000036639 antigens Human genes 0.000 description 15
• 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 description 14
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
• 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 13
• 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 13
• 238000003556 assay Methods 0.000 description 13
• 230000007423 decrease Effects 0.000 description 12
• 210000002865 immune cell Anatomy 0.000 description 12
• 210000003071 memory t lymphocyte Anatomy 0.000 description 12
• 239000005089 Luciferase Substances 0.000 description 11
• 241001465754 Metazoa Species 0.000 description 11
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 11
• 238000012809 post-inoculation Methods 0.000 description 11
• 235000002639 sodium chloride Nutrition 0.000 description 11
• 230000000638 stimulation Effects 0.000 description 11
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 10
• 210000004899 c-terminal region Anatomy 0.000 description 10
• 210000000170 cell membrane Anatomy 0.000 description 10
• 238000001727 in vivo Methods 0.000 description 10
• 230000003834 intracellular effect Effects 0.000 description 10
• 239000012528 membrane Substances 0.000 description 10
• 230000004044 response Effects 0.000 description 10
• 235000004400 serine Nutrition 0.000 description 10
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 9
• 108060001084 Luciferase Proteins 0.000 description 9
• 210000003719 b-lymphocyte Anatomy 0.000 description 9
• 210000004379 membrane Anatomy 0.000 description 9
• 239000000546 pharmaceutical excipient Substances 0.000 description 9
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
• 210000000952 spleen Anatomy 0.000 description 9
• 102000008096 B7-H1 Antigen Human genes 0.000 description 8
• 238000002965 ELISA Methods 0.000 description 8
• 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 8
• 108060003951 Immunoglobulin Proteins 0.000 description 8
• 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 8
• 239000002202 Polyethylene glycol Substances 0.000 description 8
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 8
• 230000006907 apoptotic process Effects 0.000 description 8
• 230000000139 costimulatory effect Effects 0.000 description 8
• 239000000499 gel Substances 0.000 description 8
• 230000028993 immune response Effects 0.000 description 8
• 102000018358 immunoglobulin Human genes 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 229920001223 polyethylene glycol Polymers 0.000 description 8
• 210000001519 tissue Anatomy 0.000 description 8
• 239000013603 viral vector Substances 0.000 description 8
• 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 7
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 7
• 239000004473 Threonine Chemical group 0.000 description 7
• 238000013270 controlled release Methods 0.000 description 7
• 230000016396 cytokine production Effects 0.000 description 7
• 230000001419 dependent effect Effects 0.000 description 7
• 239000000539 dimer Substances 0.000 description 7
• 230000037361 pathway Effects 0.000 description 7
• 235000013930 proline Nutrition 0.000 description 7
• 150000003839 salts Chemical class 0.000 description 7
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 7
• 235000008521 threonine Nutrition 0.000 description 7
• 239000013598 vector Substances 0.000 description 7
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 6
• 102100027207 CD27 antigen Human genes 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 6
• 101001018097 Homo sapiens L-selectin Proteins 0.000 description 6
• 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 6
• 102100033467 L-selectin Human genes 0.000 description 6
• 102000018697 Membrane Proteins Human genes 0.000 description 6
• 108010052285 Membrane Proteins Proteins 0.000 description 6
• 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 6
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
• 210000000612 antigen-presenting cell Anatomy 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 238000010276 construction Methods 0.000 description 6
• 239000013078 crystal Substances 0.000 description 6
• 210000004443 dendritic cell Anatomy 0.000 description 6
• 239000002552 dosage form Substances 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 230000002708 enhancing effect Effects 0.000 description 6
• 238000009169 immunotherapy Methods 0.000 description 6
• 239000002502 liposome Substances 0.000 description 6
• 210000001165 lymph node Anatomy 0.000 description 6
• 210000004698 lymphocyte Anatomy 0.000 description 6
• 239000000243 solution Substances 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 239000003981 vehicle Substances 0.000 description 6
• 230000003612 virological effect Effects 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 239000004475 Arginine Chemical group 0.000 description 5
• 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 5
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
• 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 5
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 5
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 5
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
• 108091028043 Nucleic acid sequence Proteins 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 238000000692 Student's t-test Methods 0.000 description 5
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
• 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 5
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
• 235000009697 arginine Nutrition 0.000 description 5
• 230000000903 blocking effect Effects 0.000 description 5
• 230000001413 cellular effect Effects 0.000 description 5
• 201000010989 colorectal carcinoma Diseases 0.000 description 5
• 210000002950 fibroblast Anatomy 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 230000013595 glycosylation Effects 0.000 description 5
• 238000006206 glycosylation reaction Methods 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 230000036541 health Effects 0.000 description 5
• 102000057310 human KLRC1 Human genes 0.000 description 5
• 210000005260 human cell Anatomy 0.000 description 5
• 210000000987 immune system Anatomy 0.000 description 5
• 230000001939 inductive effect Effects 0.000 description 5
• 230000008595 infiltration Effects 0.000 description 5
• 238000001764 infiltration Methods 0.000 description 5
• 210000003292 kidney cell Anatomy 0.000 description 5
• 210000000265 leukocyte Anatomy 0.000 description 5
• 230000000670 limiting effect Effects 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 210000004185 liver Anatomy 0.000 description 5
• 229920002521 macromolecule Polymers 0.000 description 5
• 210000004962 mammalian cell Anatomy 0.000 description 5
• 239000000178 monomer Substances 0.000 description 5
• 230000001105 regulatory effect Effects 0.000 description 5
• 238000007619 statistical method Methods 0.000 description 5
• 210000000130 stem cell Anatomy 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 241000701161 unidentified adenovirus Species 0.000 description 5
• 241001430294 unidentified retrovirus Species 0.000 description 5
• 238000011144 upstream manufacturing Methods 0.000 description 5
• 108010084313 CD58 Antigens Proteins 0.000 description 4
• 102000047934 Caspase-3/7 Human genes 0.000 description 4
• 108700037887 Caspase-3/7 Proteins 0.000 description 4
• 241000282693 Cercopithecidae Species 0.000 description 4
• 101000609767 Dromaius novaehollandiae Ovalbumin Proteins 0.000 description 4
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
• 230000006052 T cell proliferation Effects 0.000 description 4
• 102100034924 T-lymphocyte activation antigen CD86 Human genes 0.000 description 4
• 108700012920 TNF Proteins 0.000 description 4
• 238000004873 anchoring Methods 0.000 description 4
• 229940127089 cytotoxic agent Drugs 0.000 description 4
• 238000001514 detection method Methods 0.000 description 4
• 230000001900 immune effect Effects 0.000 description 4
• 230000036039 immunity Effects 0.000 description 4
• 230000010354 integration Effects 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 210000001616 monocyte Anatomy 0.000 description 4
• 229940124531 pharmaceutical excipient Drugs 0.000 description 4
• 239000013641 positive control Substances 0.000 description 4
• 230000003248 secreting effect Effects 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 210000004988 splenocyte Anatomy 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 238000013268 sustained release Methods 0.000 description 4
• 239000012730 sustained-release form Substances 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 102000003390 tumor necrosis factor Human genes 0.000 description 4
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
• ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 3
• 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 3
• 108090000342 C-Type Lectins Proteins 0.000 description 3
• 102000003930 C-Type Lectins Human genes 0.000 description 3
• 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 description 3
• 102100032912 CD44 antigen Human genes 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 108020004705 Codon Proteins 0.000 description 3
• 208000035473 Communicable disease Diseases 0.000 description 3
• 241000701022 Cytomegalovirus Species 0.000 description 3
• 108020004414 DNA Proteins 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 101100273713 Homo sapiens CD2 gene Proteins 0.000 description 3
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
• 101000712669 Homo sapiens TGF-beta receptor type-2 Proteins 0.000 description 3
• 206010062016 Immunosuppression Diseases 0.000 description 3
• 108090000174 Interleukin-10 Proteins 0.000 description 3
• 102000013691 Interleukin-17 Human genes 0.000 description 3
• 108050003558 Interleukin-17 Proteins 0.000 description 3
• 108010002350 Interleukin-2 Proteins 0.000 description 3
• 108090000978 Interleukin-4 Proteins 0.000 description 3
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
• 101000611935 Mus musculus Programmed cell death protein 1 Proteins 0.000 description 3
• 108700026226 TATA Box Proteins 0.000 description 3
• 101710183617 Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
• 230000001093 anti-cancer Effects 0.000 description 3
• 230000000840 anti-viral effect Effects 0.000 description 3
• 230000002155 anti-virotic effect Effects 0.000 description 3
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
• 235000003704 aspartic acid Nutrition 0.000 description 3
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
• 210000000481 breast Anatomy 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
• 231100000599 cytotoxic agent Toxicity 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• 238000006471 dimerization reaction Methods 0.000 description 3
• 230000004064 dysfunction Effects 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 235000004554 glutamine Nutrition 0.000 description 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Chemical group OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
• 235000014304 histidine Nutrition 0.000 description 3
• 102000046585 human CD48 Human genes 0.000 description 3
• 102000049849 human CD86 Human genes 0.000 description 3
• 102000048362 human PDCD1 Human genes 0.000 description 3
• 102000046571 human SLAMF6 Human genes 0.000 description 3
• 102000054783 human TGFBR2 Human genes 0.000 description 3
• 108091008042 inhibitory receptors Proteins 0.000 description 3
• 239000007928 intraperitoneal injection Substances 0.000 description 3
• 208000002551 irritable bowel syndrome Diseases 0.000 description 3
• 210000005229 liver cell Anatomy 0.000 description 3
• 210000003563 lymphoid tissue Anatomy 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 208000037819 metastatic cancer Diseases 0.000 description 3
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
• 210000000581 natural killer T-cell Anatomy 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 230000008488 polyadenylation Effects 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 230000005180 public health Effects 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• 108090000672 Annexin A5 Proteins 0.000 description 2
• 102000004121 Annexin A5 Human genes 0.000 description 2
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
• 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 2
• 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 2
• 102000010910 CD28 Antigens Human genes 0.000 description 2
• 108010062433 CD28 Antigens Proteins 0.000 description 2
• 108091033409 CRISPR Proteins 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
• 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 2
• 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 2
• 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
• 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
• 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 2
• 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
• 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 108090000176 Interleukin-13 Proteins 0.000 description 2
• 108010002616 Interleukin-5 Proteins 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical group OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
• 239000004472 Lysine Chemical group 0.000 description 2
• 210000004322 M2 macrophage Anatomy 0.000 description 2
• 108091054437 MHC class I family Proteins 0.000 description 2
• 102000043129 MHC class I family Human genes 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 241000713333 Mouse mammary tumor virus Species 0.000 description 2
• 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
• 102000038030 PI3Ks Human genes 0.000 description 2
• 108091007960 PI3Ks Proteins 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 101710161551 Pectate lyase 3 Proteins 0.000 description 2
• 241000710961 Semliki Forest virus Species 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• 108091008874 T cell receptors Proteins 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 description 2
• 102000008579 Transposases Human genes 0.000 description 2
• 108010020764 Transposases Proteins 0.000 description 2
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
• 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
• 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 2
• 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 2
• 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 2
• 108700005077 Viral Genes Proteins 0.000 description 2
• 230000021736 acetylation Effects 0.000 description 2
• 238000006640 acetylation reaction Methods 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 239000002269 analeptic agent Substances 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 229960003852 atezolizumab Drugs 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
• 238000012575 bio-layer interferometry Methods 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 239000002981 blocking agent Substances 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 210000003690 classically activated macrophage Anatomy 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 150000001875 compounds Chemical class 0.000 description 2
• XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 239000002254 cytotoxic agent Substances 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 210000000887 face Anatomy 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
• 102000034356 gene-regulatory proteins Human genes 0.000 description 2
• 108091006104 gene-regulatory proteins Proteins 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 150000002333 glycines Chemical class 0.000 description 2
• 210000003714 granulocyte Anatomy 0.000 description 2
• 210000002443 helper t lymphocyte Anatomy 0.000 description 2
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
• 102000054189 human CD80 Human genes 0.000 description 2
• 229940126546 immune checkpoint molecule Drugs 0.000 description 2
• 210000005008 immunosuppressive cell Anatomy 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 238000011081 inoculation Methods 0.000 description 2
• 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 2
• 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 2
• 108010074109 interleukin-22 Proteins 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• 235000014705 isoleucine Nutrition 0.000 description 2
• 230000001926 lymphatic effect Effects 0.000 description 2
• 235000018977 lysine Nutrition 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000003285 pharmacodynamic effect Effects 0.000 description 2
• 230000002974 pharmacogenomic effect Effects 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 108091033319 polynucleotide Proteins 0.000 description 2
• 102000040430 polynucleotide Human genes 0.000 description 2
• 239000002157 polynucleotide Substances 0.000 description 2
• 108010026466 polyproline Proteins 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 239000012857 radioactive material Substances 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 208000011581 secondary neoplasm Diseases 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 238000009097 single-agent therapy Methods 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 210000002536 stromal cell Anatomy 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 229940066453 tecentriq Drugs 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 210000001541 thymus gland Anatomy 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
• 210000004981 tumor-associated macrophage Anatomy 0.000 description 2
• 229950005972 urelumab Drugs 0.000 description 2
• FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
• BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
• MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
• NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
• WLKSPGHQGFFKGE-UHFFFAOYSA-N 1-chloropropan-2-yl n-(3-chlorophenyl)carbamate Chemical compound ClCC(C)OC(=O)NC1=CC=CC(Cl)=C1 WLKSPGHQGFFKGE-UHFFFAOYSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
• ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 235000006491 Acacia senegal Nutrition 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 101001094887 Ambrosia artemisiifolia Pectate lyase 1 Proteins 0.000 description 1
• 101001123576 Ambrosia artemisiifolia Pectate lyase 2 Proteins 0.000 description 1
• 101001123572 Ambrosia artemisiifolia Pectate lyase 3 Proteins 0.000 description 1
• 101000573177 Ambrosia artemisiifolia Pectate lyase 5 Proteins 0.000 description 1
• 102000006306 Antigen Receptors Human genes 0.000 description 1
• 108010083359 Antigen Receptors Proteins 0.000 description 1
• 101100162824 Arabidopsis thaliana AP2M gene Proteins 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010055113 Breast cancer metastatic Diseases 0.000 description 1
• 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
• 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
• 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
• 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
• 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 1
• 108010029697 CD40 Ligand Proteins 0.000 description 1
• 229940123189 CD40 agonist Drugs 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• 102100032937 CD40 ligand Human genes 0.000 description 1
• 238000010354 CRISPR gene editing Methods 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 108090000565 Capsid Proteins Proteins 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 102100023321 Ceruloplasmin Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 229920001661 Chitosan Polymers 0.000 description 1
• 241000282552 Chlorocebus aethiops Species 0.000 description 1
• 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 206010055114 Colon cancer metastatic Diseases 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 description 1
• 101710112752 Cytotoxin Proteins 0.000 description 1
• FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 241000252212 Danio rerio Species 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
• 208000027244 Dysbiosis Diseases 0.000 description 1
• 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
• 108010001498 Galectin 1 Proteins 0.000 description 1
• 102100021736 Galectin-1 Human genes 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000001398 Granzyme Human genes 0.000 description 1
• 108060005986 Granzyme Proteins 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 101150031823 HSP70 gene Proteins 0.000 description 1
• 206010066476 Haematological malignancy Diseases 0.000 description 1
• 101100508941 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) ppa gene Proteins 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
• 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
• 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
• 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
• 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 1
• 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
• 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
• 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 description 1
• 101000916628 Homo sapiens Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
• 101000785887 Homo sapiens Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit alpha isoform Proteins 0.000 description 1
• 101001004924 Homo sapiens Transforming growth factor beta activator LRRC32 Proteins 0.000 description 1
• 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 1
• 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 102100026214 Indian hedgehog protein Human genes 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
• 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102100035014 Interleukin-17 receptor B Human genes 0.000 description 1
• 101710186071 Interleukin-17 receptor B Proteins 0.000 description 1
• 102100036672 Interleukin-23 receptor Human genes 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• 108010092694 L-Selectin Proteins 0.000 description 1
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
• RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
• XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical compound C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 description 1
• 102000016551 L-selectin Human genes 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
• 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 101710091439 Major capsid protein 1 Proteins 0.000 description 1
• 208000001826 Marfan syndrome Diseases 0.000 description 1
• 108091027974 Mature messenger RNA Proteins 0.000 description 1
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
• 206010028116 Mucosal inflammation Diseases 0.000 description 1
• 201000010927 Mucositis Diseases 0.000 description 1
• 101100153533 Mus musculus Ltbr gene Proteins 0.000 description 1
• 101001117316 Mus musculus Programmed cell death 1 ligand 1 Proteins 0.000 description 1
• 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
• 101000863875 Mus musculus Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 108010039435 NK Cell Lectin-Like Receptors Proteins 0.000 description 1
• 102000015223 NK Cell Lectin-Like Receptors Human genes 0.000 description 1
• 230000006051 NK cell activation Effects 0.000 description 1
• 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
• 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
• 102100028762 Neuropilin-1 Human genes 0.000 description 1
• 108090000772 Neuropilin-1 Proteins 0.000 description 1
• 102000004473 OX40 Ligand Human genes 0.000 description 1
• 108010042215 OX40 Ligand Proteins 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 108010058846 Ovalbumin Proteins 0.000 description 1
• 240000007019 Oxalis corniculata Species 0.000 description 1
• 241000282577 Pan troglodytes Species 0.000 description 1
• 241001504519 Papio ursinus Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 229920000037 Polyproline Polymers 0.000 description 1
• 208000037062 Polyps Diseases 0.000 description 1
• 108050000258 Prostaglandin D receptors Proteins 0.000 description 1
• 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
• 102000012515 Protein kinase domains Human genes 0.000 description 1
• 108050002122 Protein kinase domains Proteins 0.000 description 1
• 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
• 102000009572 RNA Polymerase II Human genes 0.000 description 1
• 108010009460 RNA Polymerase II Proteins 0.000 description 1
• 230000006819 RNA synthesis Effects 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 102000018120 Recombinases Human genes 0.000 description 1
• 108010091086 Recombinases Proteins 0.000 description 1
• 206010070308 Refractory cancer Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 101710097986 SH2 domain-containing protein 1B Proteins 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
• 102100026282 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit alpha isoform Human genes 0.000 description 1
• 102000010841 Signaling Lymphocytic Activation Molecule Family Human genes 0.000 description 1
• 108010062314 Signaling Lymphocytic Activation Molecule Family Proteins 0.000 description 1
• 241000710960 Sindbis virus Species 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 230000005867 T cell response Effects 0.000 description 1
• 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
• 238000010459 TALEN Methods 0.000 description 1
• 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
• 101710084191 TGF-beta receptor type-1 Proteins 0.000 description 1
• 210000000068 Th17 cell Anatomy 0.000 description 1
• 210000004241 Th2 cell Anatomy 0.000 description 1
• 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
• 108700009124 Transcription Initiation Site Proteins 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
• 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
• 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 1
• 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 1
• 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
• 101710128896 Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 244000000188 Vaccinium ovalifolium Species 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 208000021017 Weight Gain Diseases 0.000 description 1
• 208000033779 X-linked lymphoproliferative disease Diseases 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 229960004050 aminobenzoic acid Drugs 0.000 description 1
• 229960002684 aminocaproic acid Drugs 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000005809 anti-tumor immunity Effects 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 230000005975 antitumor immune response Effects 0.000 description 1
• 208000007474 aortic aneurysm Diseases 0.000 description 1
• 230000004596 appetite loss Effects 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 230000010455 autoregulation Effects 0.000 description 1
• 239000012752 auxiliary agent Substances 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
• 230000002457 bidirectional effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000025084 cell cycle arrest Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 230000010001 cellular homeostasis Effects 0.000 description 1
• 230000030570 cellular localization Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 239000012539 chromatography resin Substances 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 235000013477 citrulline Nutrition 0.000 description 1
• 229960002173 citrulline Drugs 0.000 description 1
• 239000012459 cleaning agent Substances 0.000 description 1
• 238000012411 cloning technique Methods 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 108091008034 costimulatory receptors Proteins 0.000 description 1
• 238000012866 crystallographic experiment Methods 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 230000001461 cytolytic effect Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 230000006240 deamidation Effects 0.000 description 1
• 101150047356 dec-1 gene Proteins 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 229940124447 delivery agent Drugs 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 238000007908 dry granulation Methods 0.000 description 1
• 230000007140 dysbiosis Effects 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 238000001400 expression cloning Methods 0.000 description 1
• 210000004700 fetal blood Anatomy 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 206010016766 flatulence Diseases 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 238000001298 force spectroscopy Methods 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 238000010230 functional analysis Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 238000010362 genome editing Methods 0.000 description 1
• 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Chemical group 0.000 description 1
• 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 102000048338 human CD244 Human genes 0.000 description 1
• 102000053925 human CSF1 Human genes 0.000 description 1
• 102000043321 human CTLA4 Human genes 0.000 description 1
• 210000003917 human chromosome Anatomy 0.000 description 1
• 230000004727 humoral immunity Effects 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 229960001507 ibrutinib Drugs 0.000 description 1
• XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
• 230000008102 immune modulation Effects 0.000 description 1
• 230000008073 immune recognition Effects 0.000 description 1
• 230000005917 in vivo anti-tumor Effects 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 238000011221 initial treatment Methods 0.000 description 1
• 108091005434 innate immune receptors Proteins 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 description 1
• 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 1
• 108040007659 interleukin-33 receptor activity proteins Proteins 0.000 description 1
• 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 230000029226 lipidation Effects 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 230000001050 lubricating effect Effects 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000001365 lymphatic vessel Anatomy 0.000 description 1
• 230000001589 lymphoproliferative effect Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 201000006512 mast cell neoplasm Diseases 0.000 description 1
• 208000006971 mastocytoma Diseases 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 210000003593 megakaryocyte Anatomy 0.000 description 1
• 102000006240 membrane receptors Human genes 0.000 description 1
• 108020004084 membrane receptors Proteins 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 229930182817 methionine Chemical group 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 238000007479 molecular analysis Methods 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 108091005763 multidomain proteins Proteins 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
• 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229920005615 natural polymer Polymers 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
• 108010068617 neonatal Fc receptor Proteins 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 210000004882 non-tumor cell Anatomy 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 229940092253 ovalbumin Drugs 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 210000003668 pericyte Anatomy 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 101150009573 phoA gene Proteins 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 229940071643 prefilled syringe Drugs 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 230000001686 pro-survival effect Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000009465 prokaryotic expression Effects 0.000 description 1
• 150000003148 prolines Chemical class 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 101150079601 recA gene Proteins 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
• 230000009711 regulatory function Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 102220080600 rs797046116 Human genes 0.000 description 1
• 210000002955 secretory cell Anatomy 0.000 description 1
• 235000016491 selenocysteine Nutrition 0.000 description 1
• ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
• 229940055619 selenocysteine Drugs 0.000 description 1
• 210000000717 sertoli cell Anatomy 0.000 description 1
• 239000004017 serum-free culture medium Substances 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 238000007493 shaping process Methods 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 102000035087 single-pass transmembrane proteins Human genes 0.000 description 1
• 108091005496 single-pass transmembrane proteins Proteins 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000012916 structural analysis Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 231100000617 superantigen Toxicity 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 231100000057 systemic toxicity Toxicity 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 231100000440 toxicity profile Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000002463 transducing effect Effects 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 230000005909 tumor killing Effects 0.000 description 1
• 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 230000004222 uncontrolled growth Effects 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 238000005550 wet granulation Methods 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1